Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sight Sciences Inc SGHT

Healthcare Medical Devices
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free... see more

Recent & Breaking News (NDAQ:SGHT)

New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync(TM) Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans

GlobeNewswire 1 day ago

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

GlobeNewswire 6 days ago

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

GlobeNewswire 6 days ago

Sight Sciences to Present at Two Upcoming Investor Conferences

GlobeNewswire 8 days ago

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire October 23, 2025

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

GlobeNewswire October 17, 2025

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

GlobeNewswire September 17, 2025

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

GlobeNewswire September 9, 2025

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

GlobeNewswire September 2, 2025

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

GlobeNewswire August 26, 2025

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

GlobeNewswire August 7, 2025

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

GlobeNewswire July 30, 2025

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

GlobeNewswire July 29, 2025

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

GlobeNewswire July 24, 2025

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

GlobeNewswire May 14, 2025

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

GlobeNewswire May 8, 2025

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

GlobeNewswire April 24, 2025

Sight Sciences Announces the Release of its Sustainability Report

GlobeNewswire April 23, 2025

Sight Sciences Appoints Gary Burbach to its Board of Directors

GlobeNewswire April 22, 2025

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

GlobeNewswire April 21, 2025